Geometrical Measures Obtained from Pretreatment Postcontrast T1 Weighted MRIs Predict Survival Benefits from Bevacizumab in Glioblastoma Patients.

Mostra el registre complet Registre parcial de l'ítem

  • dc.contributor.author Molina, Davidca
  • dc.contributor.author Pérez-Beteta, Juliánca
  • dc.contributor.author Martínez-González, Aliciaca
  • dc.contributor.author Sepúlveda, Juan M.ca
  • dc.contributor.author Peralta, Sergica
  • dc.contributor.author Gil-Gil, Miguel J.ca
  • dc.contributor.author Reynes, Gasparca
  • dc.contributor.author Herrero, Anaca
  • dc.contributor.author Peñas, Ramón De Lasca
  • dc.contributor.author Luque, Raquelca
  • dc.contributor.author Capellades Font, Jaumeca
  • dc.contributor.author Balaña, Carmenca
  • dc.contributor.author Pérez-García, Víctor M.ca
  • dc.date.accessioned 2016-11-25T07:38:57Z
  • dc.date.available 2016-11-25T07:38:57Z
  • dc.date.issued 2016
  • dc.description.abstract BACKGROUND: Antiangiogenic therapies for glioblastoma (GBM) such as bevacizumab (BVZ), have been unable to extend survival in large patient cohorts. However, a subset of patients having angiogenesis-dependent tumors might benefit from these therapies. Currently, there are no biomarkers allowing to discriminate responders from non-responders before the start of the therapy. METHODS: 40 patients from the randomized GENOM009 study complied the inclusion criteria (quality of images, clinical data available). Of those, 23 patients received first line temozolomide (TMZ) for eight weeks and then concomitant radiotherapy and TMZ. 17 patients received BVZ+TMZ for seven weeks and then added radiotherapy to the treatment. Clinical variables were collected, tumors segmented and several geometrical measures computed including: Contrast enhancing (CE), necrotic, and total volumes; equivalent spherical CE width; several geometric measures of the CE 'rim' geometry and a set of image texture measures. The significance of the results was studied using Kaplan-Meier and Cox proportional hazards analysis. Correlations were assessed using Spearman correlation coefficients. RESULTS: Kaplan-Meier and Cox proportional hazards analysis showed that total, CE and inner volume (p = 0.019, HR = 4.258) and geometric heterogeneity of the CE areas (p = 0.011, HR = 3.931) were significant parameters identifying response to BVZ. The group of patients with either regular CE areas (small geometric heterogeneity, median difference survival 15.88 months, p = 0.011) or those with small necrotic volume (median survival difference 14.50 months, p = 0.047) benefited substantially from BVZ. CONCLUSION: Imaging biomarkers related to the irregularity of contrast enhancing areas and the necrotic volume were able to discriminate GBM patients with a substantial survival benefit from BVZ. A prospective study is needed to validate our results.ca
  • dc.description.sponsorship This work has been supported by Ministerio de Economía y Competitividad/FEDER, Spain [grant number MTM2015-71200-R], Consejería de Educación Cultura y Deporte from Junta de Comunidades de Castilla-La Mancha, Spain [grant number PEII-2014-031-P] and James S. Mc. Donnell Foundation 21st Century Science Initiative in Mathematical and Complex Systems Approaches for Brain Cancer [Special Initiative Collaborative – Planning Grant 220020420 and Collaborative award 220020450]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
  • dc.format.mimetype application/pdfca
  • dc.identifier.citation Molina D, Pérez-Beteta J, Martínez-González A, Sepúlveda JM, Peralta S, Gil-Gil MJ. et al. Geometrical Measures Obtained from Pretreatment Postcontrast T1 Weighted MRIs Predict Survival Benefits from Bevacizumab in Glioblastoma Patients. PLoS One. 2016 Aug 24;11(8):e0161484. doi: 10.1371/journal.pone.0161484ca
  • dc.identifier.doi http://dx.doi.org/10.1371/journal.pone.0161484
  • dc.identifier.issn 1932-6203
  • dc.identifier.uri http://hdl.handle.net/10230/27602
  • dc.language.iso engca
  • dc.publisher Public Library of Science (PLoS) ca
  • dc.relation.ispartof PLoS One. 2016 Aug 24;11(8):e0161484
  • dc.rights © 2016 Molina et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.ca
  • dc.rights.accessRights info:eu-repo/semantics/openAccessca
  • dc.rights.uri https://creativecommons.org/licenses/by/4.0/ca
  • dc.subject.other Glioblastomaca
  • dc.subject.other Marcadors bioquímicsca
  • dc.title Geometrical Measures Obtained from Pretreatment Postcontrast T1 Weighted MRIs Predict Survival Benefits from Bevacizumab in Glioblastoma Patients.ca
  • dc.type info:eu-repo/semantics/articleca
  • dc.type.version info:eu-repo/semantics/publishedVersionca

Col·leccions

Articles (Hospital del Mar Research Institute)